Table 2 Efficacy and survival status by hormone receptor status and ADC sequence order

From: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

 

HR + /HER2-low MBC (n = 56)

HR-/HER2-low MBC (n = 28)

ADC sequence order

SG → TDXd 24 (42.9%)

TDXd → SG 32 (57.1%)

SG → TDXd 25 (89.3%)

TDXd → SG 3 (10.7%)

Median total lines of therapy prior for MBC prior to ADC1, number (range)

3.0 (0–9)

4.5 (2–10)

2.0 (0–5)

3.0 (1–5)

Median lines of chemotherapy for MBC prior to ADC1, number (range)

2.0 (0–7)

2.0 (0–6)

1.0 (0–4)

2.0 (0–3)

Use of intervening therapy between ADCs, n (%)

12 (50.0%)

13 (40.6%)

9 (36.0%)

2 (66.7%)

Real-world response rate by investigator assessment, n (%)

 ADC1

17/22 (77.3%)

15/32 (46.9%)

17/25 (68.0%)

1/3 (33.3%)

 ADC2a

8/23 (34.8%)

5/29 (17.2%)

7/21 (33.3%)

0/2 (0.0%)

Median TTF, mo

 ADC1

6.3

5.3

7.5

Undeterminedb

 ADC2

3.6

2.1

2.8

Undeterminedb

Median rwOS, mo

 ADC1

22.8

17.7

16.5

Undeterminedb

 ADC2

7.8

5.8

6.5

Undeterminedb

  1. ADC antibody drug conjugate, HR hormone receptor, MBC metastatic breast cancer, SG sacituzumab govitecan, T-DXd trastuzumab deruxtecan, ADC1 first antibody drug conjugate, ADC2 second antibody drug conjugate, TTF time to treatment failure, rwOS real world overall survival.
  2. aSeveral responses for ADC2 are not evaluable given patients discontinued therapy prior to first scan, hence change in denominator.
  3. bUndetermined due to small sample size.
Back to article page